Document:

Exhibit 10.14

 

AMENDMENT
#1

 

TO THE

 

 LICENSE
AGREEMENT

 

BETWEEN

 

BREATHING
TECHNOLOGIES, INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

CASE NO. SD2010-344

 

 

 

 

    	- 1 -

    	 

    

 

LICENSE
AMENDMENT #1

 

This first
amendment ("Amendment #1) to the license agreement serial #2014-11-0249 ("Agreement") is made by and between Breathing
Technologies, Inc., a Delaware corporation having an address at 1650 Spruce Street, Suite 500, Riverside, CA. 92507 ("LICENSEE")
and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111
Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus ("UCSD")
having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla,
California 92093-0910.

 

This Amendment
#1 is effective as of the date of last signature ("Amendment #1 Date").

 

RECITALS

 

WHEREAS,
the Agreement contains certain due diligence provisions which necessarily must follow the receipt of IRB Approval by UNIVERSITY.
While IRB Approval was received in a timely manner as anticipated under the Agreement, initial patient testing revealed certain
necessary amendments to the IRB approved protocol. During this time period, patient testing was suspended by UNIVERSITY and a
revised patient testing protocol was submitted and subsequently approved by the IRB. To address this temporary suspension of patient
testing work by UNIVERSITY, the due dates for certain Due Diligence provisions in the Agreement must necessarily be extended.

 

NOW, THEREFORE,
the parties hereby agree as follows:

 

1.         Paragraph
3.3(a) in the Agreement shall be replaced in its entirety to now read:

 

"(a)      LICENSEE
shall directly or through its Affilitate(s) and/or Sublicensee(s);

 

(i)diligently
proceed with the development, manufacture and sale of Licensed Products;

 

(ii)provide
a manufacturability assessment of a Licensed Product within twelve (12) months following the Effective Date. Said assessment shall
include but not be limited to, the bill-of-materials, schematic diagrams and cost-of-goods for the intended embodiment of the
Licensed Product that will be presented for regulatory clearance;

 

(iii)provide
a written quote from a contract manufacturer capable of producing the Licensed Product identified in Paragraph 3.3(a)(ii),
at scale and in compliance with all regulations governing the manufacture of medical devices for sale into the United
States of America, within fifteen (15) months following the Effective Date;

 

    	- 2 -

    	 

    

 

(iv)provide
a written strategy document for the regulatory approval of a Licensed Product through the US Food and Drug Administration, within
eighteen (18) months of the Effective Date;

 

(v)demonstrate
construction of three (3) prototype Licensed Products in the form that will be submitted for US Food and Drug Administration clearance
within eighteen (18) months of the Effective Date;

 

(vi)submit
for 510(k) clearance with the US Food and Drug Administration within six (6) months of the conclusion of the POC Grant;

 

(vii)market
Licensed Products in the United States of America within six (6) months of receiving regulatory approval to market such Licensed
Products;

 

(viii)achieve
a first commercial sale of a Licensed Product within one (1) year of receiving regulatory approval to market such Licensed Products
in the United States of America;

 

(ix)achieve
a first commercial sale of a Licensed Product in China or Europe within three (3) years of receiving regulatory approval to market
Licensed Products in the United States of America subject to export approval, as needed;

 

(x)use
commercially reasonable efforts to fill the market demand for Licensed Products following commencement of marketing at any time
during the term of this Agreement, where commercially reasonable shall not include shelving a Licensed Product or otherwise ceasing
to develop, manufacture, sell and fill the market demand for Licensed Products for a period greater than six (6) months during
the Term; and

 

(xi)be
responsible that all necessary governmental approvals are obtained for the manufacture, use and sale of Licensed Products."

 

All other
terms of the Agreement remain unchanged.

 

    	- 3 -

    	 

    

 

IN
WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Amendment #1, in duplicate originals, by their respective
and duly authorized officers on the day and year written.

  

	BREATHING
    TECHNOLOGIES, INC:	 	THE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA:
	 	 	 	 	 
	By:	/s/
Amro Albanna	 	By:	/s/
    Jame
    Moores                                   
	 	(Signature)	 	 	(Signature)
	 	 	 	For	 
	Amro
    Albanna	 	Jane Moores,
    Ph.D.
	CEO	 	Assistant
    Vice Chancellor-Technology Transfer
	 	 	 	 	 
	Date:	July 31,
    2014           	 	Date:	8/6/2014            

 

 

-
4 -Exhibit 10.18

 

MANAGEMENT
SERVICES AGREEMENT

 

This
Management Services Agreement (the "Agreement") is entered into as of this lth day of January, 2013, (the "Effective
Date") by and between Innovation Economy Corp. a Delaware corporation (hereinafter be referred to as "IEC"), and
Nano Engineered Applications, Inc., a Delaware corporation (hereinafter referred to as "NEA"). IEC and NEA are occasionally
referred to herein individually as a "Party" and collectively as the "Parties."

 

WHEREAS,
NEA wishes to engage IEC to provide managements services, administration, finance, accounting and other corporate functions.

 

WHEREAS,
NEA is a 85.45% owned subsidiary of IEC and IEC provides management services on a recurring basis;

 

WHEREAS,
IEC hereby agrees to strictly serve NEA as a management resource for the purpose of current operations, administration, finance,
accounting and other corporate functions, for NEA and such other lawful purposes as agreed to by the Parties hereto from time
to time.

 

NOW,
THEREFORE, in consideration of the mutual promises hereinafter set forth, the sufficiency of which are hereby acknowledged, IEC
and NEA agree as follows:

 

	A.	Management
                                         Services. NEA hereby authorizes IEC, on a non-exclusive basis, to provide
                                         managements services, administration, finance, accounting and other corporate functions.

 

	B.	Acceptance
                                         of Management Services. NEA accepts Management Services from IEC, on a non-exclusive
                                         basis.

 

	C.	Fee.
                                         NEA shall retain IEC on a fee basis of $14,229 monthly.IEC's management services
                                         hereunder are subject to the following:

 

i)         Nonexclusive
Right. For the term of this agreement, IEC shall have the nonexclusive right to provide Management Services to other IEC subsidiaries
and affiliated companies.

 

ii)        Rote.
IEC understands and agrees that he will only provide direct Introduction between the NEA and the potential Qualified Investors.
IEC will not discuss the merits or details of any Transaction and will not deliver or provide legal documents between NEA and
the Qualified Investor.

 

iii)       Limitations.
IEC represents, warrants and covenants that he does not enter into similar arrangements with companies on a regular basis and
that IEC does not engage in such other activities that would otherwise require IEC to register as a "broker" as that
term is defined in Section 15(a) of the Securities Exchange Act of 1934, as

 

	D.	Reserved.

 

	E.	Reserved.

 

	F.	Expiration
    of the Agreement. The term of this Agreement shall begin on the effective date of this Agreement, first written above,
    and end on December 31, 2014. The NEA may terminate this Agreement for any reason with thirty days (30) notice to IEC. This
    Agreement may be extended beyond the Term by mutual written consent of each party.

 

	G.	Waiver.
    No delay in exercising, no course of dealing with respect to, or no partial exercise of any right or remedy hereunder shall
    constitute a waiver of any other right or remedy, or future exercise thereof.

  

    	1

    	 

    

 

	H.	Severability.
    If any term or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable,
    all terms, provisions, covenants, and conditions and all applications not held invalid, void, or unenforceable will continue
    in full force and will in no way be affected, impaired, or invalidated.

 

	I.	Notice.
    Written notice by any Party to the other shall be deemed to have been given when received via certified mail by the intended
    recipient thereof at its address shown on the signature page hereof, or to such other address as such intended recipient may
    specify in a written notice pursuant hereto.

 

	J.	Governing
    Law. The validity and interpretation of this Agreement shall be governed by, and construed and enforced in accordance
    with, the laws of the State of Delaware applicable to agreements made and to be fully performed therein (excluding the conflicts
    of law rules). Each of the Company and IEC(and, to the extent permitted by law, on behalf of their respective equity holders
    and creditors) hereby knowingly, voluntarily and irrevocably waives any right it may have to a trial by jury in respect of
    any claim based upon, arising out of or in connection with this Agreement or any of the agreements or transactions contemplated
    hereby or thereby.

 

	K.	Entire
    Agreement: Amendment. This Agreement constitutes the entire Agreement among the Parties with respect to the subject matter
    hereof and supersedes in all respects all prior proposals, negotiations, conversations, discussions and agreements between
    the Parties. This Agreement may not be modified or amended except by express written amendment signed by authorized representatives
    of all Parties.

 

	L.	Attorneys'
    Fees. If any Party hereto commences an action against another Party to enforce any of the terms hereof or because of the
    breach by such other Party of any of the terms hereof, the prevailing Party shall be entitled, in addition to any other relief
    granted, to all actual out-of-pocket costs and expenses incurred by such prevailing Party in connection with such action and
    the enforcement and collection of any judgment rendered therein, including, without limitation, all reasonable attorneys'
    fees, IEC fees and expert witness fees, and a right to such costs and expenses shall be deemed to have accrued upon the commencement
    of such action and shall be enforceable whether or not such action is prosecuted to judgment.

 

	M.	Execution
    of the Agreement. IEC and the party executing this Agreement on behalf of the NEA has the requisite corporate power and
    authority to enter into and carry out the terms and conditions of this Agreement, as well as all transactions contemplated
    hereunder. All corporate proceedings have been taken and all corporate authorizations and approvals have been secured which
    are necessary to authorize the execution, delivery and performance by NEA of this Agreement. This Agreement has been duly
    and validly executed and delivered by NEA and constitutes the valid and binding obligations of NEA, enforceable in accordance
    with the respective terms. Upon delivery of this Agreement to Consultant, this Agreement, and the other agreements referred
    to herein, will constitute the valid and binding obligations of NEA, and will be enforceable in accordance with their respective
    terms.

 

	N.	Successors
    & Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective
    heirs, personal representatives and successors and assigns.

 

	O.	Preparation of Agreement.
    The Parties have participated jointly in the negotiation and drafting of this Agreement and each provision hereof. In the
    event any ambiguity, conflict, omission or other question of intent or interpretation arises, this Agreement shall be construed
    as if jointly drafted by the Parties, and no presumption or burden of proof shall be presumed, implied or otherwise construed
    favoring or disfavoring any Party by virtue of the authorship of this Agreement or of any provision hereof.

 

    	2

    	 

    

 

	P.	Headings.
    The headings and any table of contents contained in this Agreement are for reference purposes only and shall not in any way
    affect the meaning or interpretation of this Agreement.

 

	Q.	Agreement
    to Perform Necessary Acts. IEC and the NEA agree to perform any further acts and execute and deliver any documents that
    may be reasonably necessary to carry out the provisions of this Agreement.

 

	R.	Non-Disclosure.
    Except as may be required by law, neither IEC nor the NEA shall disclose the financial terms of this Agreement to persons
    not involved in the operation of the NEA, and the Parties shall disclose the fmancial terms of the Agreement to those involved
    in the operation of the NEA only as needed to implement the terms of the Agreement or carry out the operations of the NEA.
    Notwithstanding the foregoing, each Party may disclose this Agreement: (i) to their attorneys and to any court as necessary
    to enforce the provisions of this Agreement; (ii) to their accountants, and to the Internal Revenue Service and the Franchise
    Tax Board as necessary to prepare for their federal and state tax returns; (iii) in accordance with the Parties' respective
    disclosure obligation under state and federal securities law including, without limitation, the Securities Exchange Act of
    1933 and/or 1934; (iv) any disclosure required by OTC Markets (a.k.a Pink OTC Markets); and, (iv) to such persons as required
    by law or court order.

 

	S.	Rights
    Cumulative. The rights and remedies provided by this Agreement are cumulative, and the exercise of any right or remedy
    by either Party hereto (or by its successors), whether pursuant to this Agreement, to any other agreement, or to law, shall
    not preclude or waive its right to exercise any or all other rights and remedies.

 

	T.	Facsimile
    Certification. A facsimile copy of this Agreement signed by any and/or all Parties shall have the same binding and legal
    effect as an original of the same.

 

	U.	Counterparts.
    This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together
    shall constitute one in the same instrument. Regardless of whether this Agreement is executed in one or more counterparts,
    each such counterpart may be executed by actual or facsimile signature(s).

 

IN
WITNESS WHEREOF, the Parties hereto, through their duly authorized officers, have executed this Agreement, which shall be
binding as of the Effective Date.

 

	INNOVATION ECONOMY CORPORATION	 	NANO ENGINEERED APPLICATIONS, INC.
	 	 	 	 	 
	By:	 	 	By:	 
	Title:	CEO & Chairman	 	Title:	CEO & President
	Address:	1650 Spruce St., 5th Fl,	 	Address:	1650 Spruce St., 5th Fl,
	 	Riverside, CA 92507	 	 	Riverside, CA 92507
	Tel No:	951-824-8669	 	Tel No:	951-824-8669
	Fax No:	951-846-1755	 	Fax No:	951-846-1755

 

 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]